2024
Chapter 6 Clinical diagnosis and evaluation pathway
Lam R, Banini B, Do A, Lim J. Chapter 6 Clinical diagnosis and evaluation pathway. 2024, 77-100. DOI: 10.1016/b978-0-323-99649-5.00003-0.Peer-Reviewed Original Research
2023
Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosisExercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Chen G, Banini B, Do A, Gunderson C, Zaman S, Lim J. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes 2023, 14: 1811. PMID: 37761951, PMCID: PMC10531443, DOI: 10.3390/genes14091811.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseEffects of exerciseFatty liver diseaseHistological outcomesLiver histologyLiver diseaseClinical trialsHistological endpointsSystematic reviewSignificant histopathological improvementNAFLD activity scoreImpact of exerciseIndependent effectsRandom-effects modelSystematic literature searchHistopathological improvementExercise interventionActivity scoreClinical endpointsPooled estimatesMeta-AnalysisTotal participantsLiterature searchComparison group
2022
The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review
Chen G, Banini B, Do A, Lim J. The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review. Clinical And Molecular Hepatology 2022, 29: s319-s332. PMID: 36517000, PMCID: PMC10029942, DOI: 10.3350/cmh.2022.0366.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseHepatic steatosisLiver fibrosisLiver diseaseHistological endpointsIndependent effectsSystematic reviewNon-randomized interventional studyMagnetic resonance imaging-based techniquesAdditional large RCTsChronic liver diseaseSignificant histological improvementEffects of exerciseClinical outcome endpointsSystematic literature searchHistological improvementExercise interventionHepatocyte ballooningOriginal research studiesLarge RCTsOutcome endpointsInterventional studyS1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease
Ilagan-Ying Y, Schwartz A, Park E, Bollinger B, Ying L, Mehal W, Do A. S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease. The American Journal Of Gastroenterology 2022, 117: e1043-e1044. DOI: 10.14309/01.ajg.0000862452.53915.0f.Peer-Reviewed Original Research
2021
S1125 The Impact of Dietary Composition on Non-Alcoholic Fatty Liver Disease and Advanced Fibrosis in U.S. Adults
Ochoa-Allemant P, Ilagan-Ying Y, Do A. S1125 The Impact of Dietary Composition on Non-Alcoholic Fatty Liver Disease and Advanced Fibrosis in U.S. Adults. The American Journal Of Gastroenterology 2021, 116: s529-s529. DOI: 10.14309/01.ajg.0000778032.99095.98.Peer-Reviewed Original Research
2020
Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints
Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opinion On Drug Discovery 2020, 16: 125-134. PMID: 33086894, DOI: 10.1080/17460441.2020.1811674.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseaseNonalcoholic steatohepatitisLiver diseaseHealthcare resource burdenNovel trial designsClinical trial researchSignificant healthcareCase definitionClinical trialsEfficacious treatmentNew therapiesEndpoint definitionsTrial designTreatment targetsMetabolic diseasesTrial researchClinical researchDrug development processQuality data reportingDrug approvalDiseaseResource burdenRegulatory pathwaysDrug developmentS1189 Incorporation of Obesity Medicine Into the Care of Patients With Nonalcoholic Fatty Liver Disease: 1-Year Interim Results
Mankash M, Kelly M, Duffy A, Mehal W, Do A. S1189 Incorporation of Obesity Medicine Into the Care of Patients With Nonalcoholic Fatty Liver Disease: 1-Year Interim Results. The American Journal Of Gastroenterology 2020, 115: s595-s595. DOI: 10.14309/01.ajg.0000706804.10023.a3.Peer-Reviewed Original Research
2019
Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease
Do A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.Peer-Reviewed Original ResearchSuccessful weight lossFatty liver diseaseWeight lossLiver diseaseReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseWeight loss medicationsCurrent medical therapyPatient-centered approachMedical therapyPatient weightPatient evaluationMultisystemic complicationsEpidemic proportionsBehavioral change goalsNAFLDMedical approachObesityDiseaseMedicationsMultimodal approachFibrosisTreatmentSteatosisComplications1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model
Mankash M, Kelly M, Dean J, Duffy A, Mehal W, Do A. 1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model. The American Journal Of Gastroenterology 2019, 114: s599-s599. DOI: 10.14309/01.ajg.0000593756.22484.ae.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseWeight loss medicationsNonalcoholic steatohepatitisBariatric surgeryWeight lossClinical characteristicsLiver diseaseObesity managementEffective treatmentDisease programsAverage age 55Meal replacement therapySurgical weight lossWeight loss optionsAlanine aminotransferase levelsChronic liver diseaseFatty liver diseaseObstructive sleep apneaManagement of patientsCare of patientsLimited efficacy dataClinical care modelsLiver disease modelAverage weight lossHepatology clinic